Tuberculosis continues to affect about 30% of the world's population, particularly in developing countries, despite the existence of chemotherapeutic drugs and the widespread use of the Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine. Effective chemotherapeutic treatment takes a long time, is expensive, and is not available to people in the parts of the world where it is most needed. The situation is further complicated by the appearance of multidrug-resistant strains. BCG vaccination efficacy is controversial, and it seems to fail to protect adults against pulmonary tuberculosis (2, 3) . These situations justify the need to develop better methods of tuberculosis prevention and therapy.
DNA technology has been used successfully in the vaccination of animal models against infection with viruses, bacteria, and parasites as well as in antitumor therapy and treatment of autoimmunity and allergies (34) . Mycobacterium tuberculosis, the causative agent of tuberculosis, has received particular attention in this respect, and several of its proteins have been evaluated as DNA vaccines in experimental models. These include the 65-kDa heat shock protein (hsp65); the 36-kDa proline-rich antigens (32) Ag85A (13) , Ag85B, and Ag85C (23) ; the 38-kDa protein (39) ; hsp70 and the 36-and 6-kDa proteins (21) ; MPT64 (23-kDa protein), Ag85B (30-kDa protein), and ESAT-6 (6-kDa protein) (14) ; and the phosphatebinding proteins PstS-1, PstS-2, and PstS-3 (31) . CD4 ϩ T-cell responses characterized by gamma interferon (IFN-␥) secretion, CD8 ϩ cytotoxic T-lymphocyte (CTL) responses, and antibody secretion could generally be induced in these studies, and most reported protection after challenge with virulent M. tuberculosis or M. bovis BCG (13) . This protection, however, was similar to or lower than that obtained with the BCG vaccine. Recently, DNA vaccination with hsp65 was used for tuberculosis therapy in mice and showed promising results for the elimination of persistent infection (22) .
Epitope-based immunization has been shown to be protective in diverse models because of the induction-specific CTL responses it generates (15, 24, 28) . The advantages of epitope immunization, compared to protein or organismal immunization, are that an immune response is elicited only against the protective epitope (avoidance of epitope drift in the case of viral infections) and that the required type of immune response is triggered (humoral versus cellular immunity). Examples of unwanted responses include the induction of antibodies in human immunodeficiency virus (20) or tuberculosis, which can promote infection in some cases (11) . In addition, experiments with mice with the DNA vaccine encoding the 19-kDa lipoprotein of M. tuberculosis showed the induction of a nonprotective antibody-mediated immune response, rather than a T-cell response (8) . Synthetic peptide vaccination has the disadvantage of inducing weak immune responses; it is generally difficult to elicit strong CTL responses, despite the use of all types of adjuvants. DNA vaccines encoding single or multiple epitopes can circumvent these disadvantages and have been shown to induce efficient cellular immunity in different models of viruses and tumors (5, 12, 33) .
In order to evaluate the efficacy of epitope-based DNA vaccines against tuberculosis, we prepared DNA vaccines based on CTL (7) and Th cell (36) epitopes of the 38-kDa lipoglycoprotein of Mycobacterium tuberculosis and analyzed and compared their immunogenicities with that of the already described DNA vaccine pXJ38, which encodes the entire 38-kDa protein (39) . We showed that the coadministration of plasmid DNAs encoding either a Th or CTL epitope (P3) induced antigen-specific CD8 ϩ CTL and Th1 responses, which might play a major role in protection against tuberculosis. Moreover, these epitope-based DNA vaccines were unable to induce an antigen-specific humoral response. Antibodies against M. tuberculosis may be detrimental for protection against tuberculosis; therefore, epitope-based DNA vaccines may have an important advantage over other protein-based DNA vaccines for tuberculosis.
MATERIALS AND METHODS
Mice. Inbred C57BL/6 (H-2 b ) female mice were purchased from the Central Animal Laboratory of Utrecht University and used when 8 to 12 weeks old. The Ethics Committee on Animal Experimentation of Utrecht University approved these experiments.
Antigens and synthetic peptides. The 38-kDa recombinant protein was purified to homogeneity as described previously (29) . Tuberculin purified protein derivate (PPD) was obtained from Statens Serum Institute (Copenhagen Denmark). Peptides derived from the sequence of the 38-kDa protein were synthesized by R. van (39) .
Two vectors were used for constructing the plasmids containing the various epitopes: pcDNA3.1ϩ and VR1012. Both vectors consist of a pUC18 backbone with the same cytomegalovirus (CMV) promoter. They differ in the kanamycin versus the ampicillin selection markers and in the polyadenylation site. In vivo and in vitro experiments revealed no differences between the two vectors in CTL induction, cytokine production (IFN-␥), or B-cell activation (polyclonal immunoglobulin M [IgM] production) in mouse spleen cells.
Three plasmids based on Th and CTL epitopes of the 38-kDa protein of M. tuberculosis were constructed. The nucleotide sequence corresponding to the epitopes was generated by using two overlapping oligonucleotides that served as both a primer and a template. All of the forward primers included a restriction site; a Kozak sequence (GCCGCCGCC), which enhances protein expression (18) ; the ATG start codon; and a part of the nucleotide sequence of the epitope. All of the reverse primers included a part of the nucleotide sequence of the epitope, the TAG stop codon, and a restriction site. Primers for the construction of pP3, encoding the previously described P3 CTL epitope (aa 166 to 175) (7), were as follows (nucleotide sequence corresponding to the epitope in boldface): sense, ATCCGGATCCGCCGCCGCCATGATCGCTGCGTCAACCCC; antisense, GGATCTCGAGCTACAGGTTCACGCCGGGGTTGAGCG. This construct was inserted into BamHI and XhoI sites of the eukaryotic expression vector pcDNA3.1ϩ (Invitrogen, San Diego, Calif.) downstream of the CMV promoter. The primers for the construction of vTh, encoding part of the previously described Th epitope (aa 71 to 81) (36), were as follows: sense, ATC CGTCGACGCCGCCGCCATGGCCTTTCACGAGAGG; antisense, GGATGG ATCCCTAGATCGTGACGTTCGGATACCTCTCGTGA. This construct was inserted into SalI and BamHI sites of the eukaryotic expression vector VR1012 (Vical, Inc., San Diego, Calif.) downstream of the CMV promoter.
For the construction of pThP3, which contained the nucleotide sequences corresponding to the Th and CTL epitopes, the inserts encoding both epitopes were generated separately and then ligated into pcDNA3.1ϩ. The Th insert was generated with the following primers: sense, ATCCGGATCCGCCGCCGCCA TGGCCTTTCACGAGAG; antisense, GGATGAATTCGATCGTGACGTTCGG ATACCTCTCG. The primers for the P3 insert were as follows: sense, ATCCG AATTCATCGCTGCGCTCAACCCCG; antisense, GGATCTCGAGCTACAGG TTCACGCCGGGGT. Th was inserted into BamHI and EcoRI sites of the pcDNA3.1ϩ vector, while P3 was inserted between EcoRI and XhoI sites, downstream of the CMV promoter. All plasmids were cloned into Escherichia coli DH5␣, and the positive colonies were selected by PCR or restriction enzyme analysis. The nucleotide sequences of the inserts in all plasmids were confirmed by sequencing with the ABI Prism 377 (Perkin-Elmer, Norwalk, Conn.). The pcDNA3.1ϩ and VR1012 vectors, which do not encode any of the inserts, were used as controls (control vectors). Plasmid DNA was amplified in E. coli DH5␣, purified with the Qiagen plasmid purification kit (Qiagen, Inc., Chatsworth, Calif.), redissolved in phosphate-buffered saline (PBS), and maintained at Ϫ20°C until use.
Cell lines and culture medium.
), a thymoma cell line, was a gift from P. van Koten (Department of Immunology, Veterinary Faculty, Utrecht University, The Netherlands); and EX-38 (H-2 b ), an EL-4 cell line transfected with the gene encoding an M. tuberculosis 38-kDa protein, was a gift from X. Zhu and H. M. Vordermeier (VLA-Weybridge, TB Research Group, Surrey, United Kingdom) (39) . All cells were grown in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% heat-inactivated fetal calf serum, 10 g of gentamicin per ml, 2 mM glutamine, 1.7 g of NaHCO 3 , and 50 M ␤-mercaptoethanol (IMDM-complete). The transfected cell line, EX-38, was grown in IMDM-complete with G418 at a concentration of 1 mg/ml.
Immunization procedures. Mice were injected three times biweekly with 100 g of the plasmid DNA, pXJ38, vTh, pP3, pThP3, or a mixture of vTh and pP3 (vThϩpP3) (50 g of vTh plus 50 g of pP3) or with control DNA vectors (PcDNA3.1ϩ or VR1012) in the quadriceps muscle. Blood samples were collected from the retroorbital plexus, and spleens were isolated 2 weeks after the last injection.
In vitro expansion of antigen-specific CTL. After spleen isolation, cell suspensions were prepared as described previously (38) , and the erythrocytes were lysed by hypotonic shock and washed twice with IMDM. Spleen cells (30 ϫ 10 6 ) from in vivo-primed mice were cocultured with mitomycin (Sigma Chemical Co., St. Louis, Mo.)-treated EX-38 cells (1.5 ϫ 10 6 ) in a 10-ml cell suspension in IMDMcomplete for 5 to 6 days at 37°C in 5% CO 2 . Ten to 30 U of recombinant interleukin-2 (IL-2) per ml (Roche Diagnostics, Mannheim, Germany) was added after 48 h of culture.
51 Cr release assay. Cells were collected from the in vitro culture and washed once with IMDM-complete. Viable cytotoxic effector cells were separated from dead cells by centrifugation with a Lympholyte-M density gradient (820 ϫ g for 10 min), washed twice, and resuspended in RPMI 1640 supplemented with 5% fetal calf serum (CTL medium) at a concentration of 4 ϫ 10 6 cells/ml. EX-38 or EL-4 target cells (2 ϫ 10 6 ) were incubated for 1 h at 37°C with 100 Ci of 51 Cr (Amersham, Life Science, United Kingdom). After being washed three times, 5 ϫ 10 3 target cells/100 l were added to 100 l of various numbers of effector cells that had been plated in 96-well U-bottom plates. The plates were then centrifuged for 1 to 2 min at 200 ϫ g and incubated for 4 to 6 h at 37°C in 5% CO 2 . After incubation, 100 l of supernatant was collected and counted in a gamma counter. The specific lysis (percentage of cytotoxicity) was calculated with the equation % Lysis ϭ [(sample Ϫ spontaneous release)/(total release Ϫ spontaneous release)] ϫ 100%.
In the antibody-blocking experiments, either anti-mouse CD4 monoclonal antibody (MAb) (clone GK1.5) or anti-mouse CD8 MAb (clone 53-6.7) (Pharmingen, San Diego, Calif.) was added (5 g/well) to the effector cells 30 min before the 51 Cr-labeled EX-38 cells were added (39) . In vitro cytokine production and cytokine determination by ELISA. Pools of spleen cell suspensions (5 ϫ 10 6 cells) from groups of mice immunized with DNA constructs (PxJ38, ThP3, Th, and ThϩP3 or plasmid alone) were cultured in IMDM-complete in 24-well plates in the presence of 20 g of PPD per ml, 20 g of recombinant 38-kDa protein per ml, or 50 g of 38-kDa peptides (P1, P3, P4, and Th) per ml at 37°C in 5% CO 2 . Supernates were harvested after 72 h, aliquoted, and stored at Ϫ20°C until assayed for specific cytokines. IL-4 and IFN-␥ contents were measured with a commercial enzyme-linked immunosorbent assay (ELISA) kit (Genzyme Co, Cambridge, Mass.) according to the manufacturer's protocol. Results are expressed as mean cytokine level of duplicate wells after subtracting the spontaneous release of the cytokine by unstimulated cells.
Detection of IgG1 and IgG2a by ELISA. Recombinant 38-kDa protein was dissolved in 0.1 M carbonate-bicarbonate buffer (pH 9.6), while peptide P3 or Th was dissolved in PBS at a concentration of 10 g/ml. Both were then dispensed into 96-well polyvinyl microtiter plates (100 l/well) (MaxiSorp F96; Nunc, Roskilde, Denmark). Plates coated with the 38-kDa protein were incubated for 1 h at 37°C, followed by overnight incubation at 4°C; plates coated with peptide P3 or Th were incubated overnight at 37°C. Free binding sites were blocked with 3% gelatin (Merck) in PBS for 1 h at 37°C. Serial dilutions of sera were prepared in PBS-0.05% Tween 20 1% (wt/vol) milk (Protifar), dispensed into ELISA plates, and incubated for 2 h at 37°C. After incubation, the plates were washed three times with PBS-0.05% Tween 20. Then, 50 l of either biotin-conjugated mouse anti-mouse IgG2a (Igh-1b) or biotin-conjugated mouse anti-mouse IgG1 (Igh-4b) (Pharmingen) in PBS-0.05% Tween 20 3% (wt/vol) milk (Protifar) was added. After a 1-h incubation at 37°C, the plates were washed again three times and incubated with 50 l of horseradish peroxidase-conjugated streptavidin for 15 min at 37°C. After a final washing, 50 l of substrate (0.1 M NaAc-tetramethyl benzidine-30% H 2 O 2 at 10,000:400:1 [vol/vol/vol]) was added. The reaction was stopped after 20 to 30 min with 100 l of 1 M H 2 SO 4 , and the plates were read in a Titertek Multiskan MCC/340 at 450 nm. The titers were defined as the reciprocal dilution that gave an optical density of 0.5 at 450 nm.
Statistical analysis. Differences between the ability of the plasmid DNA vaccines to induce CTL were analyzed with Student's t test. P Ͻ 0.05 was considered to be significant.
RESULTS
CTL induction by DNA vaccination. C57BL/6 mice were injected intramuscularly three times biweekly with plasmid DNA encoding either the P3 CTL epitope (pP3), the Th epitope (vTh), both the Th and the CTL epitopes (pThP3), a mixture of vTh and pP3 (vThϩpP3), the positive control (pXJ38), or a control vector. Mice were tested 2 weeks after the last injection. Cytotoxic T-cell responses were determined with a classical 51 Cr release assay, after in vitro restimulation, against the target cell line EX-38, which expresses the 38-kDa protein. EL-4 was used as a negative control. DNA immunization with pXJ38 resulted in strong CTL responses (specific lysis at a target-to-effector [T:E] ratio of 1:80; 50% Ϯ 12%), which were significantly above the background level. Specific CTL induction was also observed after immunization with the vThϩpP3 mixture, which was significantly higher than the background level (T:E ratio of 1:80, P Ͻ 0.025; T:E ratio of 1:40, P Ͻ 0.05) ( Table 1) . Neither the plasmids encoding the single CTL epitope pP3 nor the plasmids with the insert corresponding to the Th and CTL epitope (pThP3) induced any specific CTL above the levels induced by the control vector. The lysis observed with EL-4 was below 4%.
DNA vaccines induce CD8
؉ cytotoxic T cells. In order to determine which effector T-cell population was primed by vaccination with plasmid DNAs, blocking experiments with anti-CD8 and anti-CD4 MAb were performed. Figure 1A and B show that the specific lysis of EX-38 cells was only blocked by the anti-CD8 MAb, not by the anti-CD4 MAb, demonstrating that the effector-specific CTL induced by pXJ38 and vThϩpP3 were CD8 ϩ T cells.
Th1 type of immune responses following DNA vaccination.
To investigate the cytokine profile induced by the different plasmid DNAs, we measured the amount of antigen-specific IL-4 and IFN-␥ produced by spleen cells from plasmid DNAimmunized mice. The spleens were collected 2 weeks after the last injection; spleen cells were restimulated in vitro with the peptides derived from the 38-kDa protein, the recombinant 38-kDa protein, or PPD. High levels of IFN-␥ were secreted by spleen cells from all plasmid DNA-vaccinated mice after in vitro stimulation with the recombinant 38-kDa protein ( Fig. 2 and Table 2 ). IL-4 production was low or not even detectable for all of the plasmid DNAs tested (Ͻ10 pg/ml) (data not shown). The cells from pXJ38-vaccinated mice recognized peptides Th, P4, and, to a lesser extent, P3, but not peptide P1 (Fig. 2) . The multiple-epitope vaccination with either vThϩpP3 or pThP3 resulted in a broader and stronger induction of IFN-␥ upon in vitro stimulation with antigens than the single-epitope plasmid DNA vTh or pP3 (Table 2) . Surprisingly, the vThϩpP3 and pThP3 DNA vaccines also primed cells that produced IFN-␥ upon stimulation with P4 peptide. PPD only stimulated IFN-␥ production in spleen cells from mice that were immunized with plasmid DNAs encoding more than one epitope (pXJ38, vThϩP3, and pThP3). In general, none of the construct-primed cells produced IFN-␥ upon stimulation with peptide P1 or P3.
T-cell epitope-based DNA vaccines do not elicit anti-38-kDa antibodies. To investigate the antigen-specific humoral response after immunization with the different plasmid DNAs, we measured anti-38-kDa antibodies in the sera of mice vaccinated with the plasmid pXJ38, vTh, pThP3, or vThϩpP3 or with a control vector. The IgG1 and IgG2a titers were determined 2 weeks after the last DNA injection. High titers of specific IgG2a were only detected in the sera from mice immunized with the plasmid pXJ38; IgG2a antibody levels in the sera of all the other DNA-immunized mice were not significantly different from those detected in the sera of mice injected with a control vector (Fig. 3) . The IgG1 titers in the sera of all tested mice were either very low (pXJ38 and vTh) or undetectable. Sera of the DNA-vaccinated mice were also tested in a peptide-based ELISA to examine the presence of anti-Th or anti-P3 antibodies; neither IgG1 nor IgG2a was detected (data not shown). 
DISCUSSION
DNA vaccines encoding various proteins of Mycobacterium tuberculosis have been tested successfully in animal models (13, 14, 21, 22, 32, 39) . So far, however, the protection achieved with those vaccines has been similar to or lower than that elicited by BCG vaccination. The future success of DNA vaccines for tuberculosis might reside in the fact that they are effective inducers of cellular immune responses mediated by the induction of IFN-␥-secreting cells and CD8 ϩ CTL. These types of responses have been shown to be crucial for protection against tuberculosis in both humans (25, 26, 30, 37) and animals (6, 9, 10) .
DNA vaccines encoding single or multiple epitopes have been shown to induce cellular immunity in different models of viruses and tumors (5, 12, 33) . Thus, the use of multipleepitope DNA vaccines may be a suitable approach to improve the current DNA vaccines for various diseases. Since this approach has not yet been evaluated for tuberculosis, we constructed DNA vaccines based on cytotoxic and Th epitopes of the 38-kDa lipoglycoprotein of M. tuberculosis and analyzed and compared their immunogenicity with that of pXJ38, a DNA vaccine encoding the entire 38-kDa protein (39) .
The ability of epitope-based DNA vaccines to induce CTL was studied with the cell line EX-38, which expresses the entire 38-kDa protein. The vThϩpP3 combination was able to induce antigen-specific CTL, demonstrating that vaccination with vThϩpP3 primes CD8 ϩ CTL, which can recognize the naturally processed 38-kDa protein. The percentage of lysis induced by the vThϩpP3 combination was half that observed with the whole-protein DNA vaccine (Table 1) . However, since the 38-kDa protein has more CTL epitopes and the target cell line used expresses the entire 38-kDa protein, it is not surprising that pXJ38 induced higher levels of CTL.
It is noteworthy that only vThϩpP3 efficiently primed CD8 
Effector cells (E) were incubated with EX-38 cells (target cells [T]) in a classical
51 Cr release assay. C57BL/6 mice were immunized intramuscularly three times biweekly with 100 g of plasmid DNA. Spleens were isolated from groups of two mice 2 weeks after the last injection, and spleen cells were pooled. CTL responses were blocked with anti-CD4 or anti-CD8 MAb. Results are representative of four independent experiments. CTL. One plausible explanation for this is that only with this combination of plasmid DNAs does good cooperation between Th and CTL functions exist. Possibly, the Th and CTL epitopes, generated after vThϩpP3 injection, are efficiently presented by the same antigen-presenting cell (APC) in the same compartment of the immune system or by the same APC, a situation that is known to lead to an effective CTL priming (1) . The failure of the pThP3 construct to induce CTL might be a consequence of the inadequate presentation of the epitopes, since both epitopes are now expressed within one peptide, and this peptide might be processed differently by the APC. Furthermore, CTL effector cells can act alone when lysing target cells, while their differentiation from naive CD8 ϩ T cells is dependent on CD4 ϩ helper cells (1, 4, 16) . IFN-␥ and IL-12 are known to be important in promoting a Th1 response and enhancing cytotoxicity during the priming and maturation of lymphocytes (35) . In contrast to the other epitope vaccines used in this study, the coadministration of vTh and pP3 plasmid DNAs (vThϩpP3) contributed more nonmethylated CpG motifs (20% more), which are known to induce Th1 cytokines such as IFN-␥ and IL-12 (17, 27) . The failure of pP3 and pThP3 to induce CD8 ϩ CTL can be partially explained by the inadequate antigen presentation by APC or the wrong cytokine milieu and, consequently, lack of priming of CTLs. However, other factors, like the deficient transcription and expression of the epitopes after injection (which needs further investigation), cannot be excluded. The inclusion of reporter genes in plasmid DNAs may reveal whether minigenes in the plasmids are being transcripted and the corresponding peptides expressed.
After in vitro stimulation with the recombinant 38-kDa protein, spleen cells from mice vaccinated with either pXJ38, pP3, vTh, pThP3, or vThϩpP3 secreted high levels of IFN-␥ (Table  2) . Small amounts or no IL-4 was detected. This suggests the induction of a Th1 type of response by all DNA plasmids tested. These results also demonstrated that epitope-based DNA vaccines primed cells that recognize the epitopes (peptides) generated from the entire 38-kDa protein after natural processing. In addition, pXJ38-, vThϩP3-, and pThP3-primed cells were also stimulated by culture filtrates of M. tuberculosis (PPD) ( Table 2) .
The epitope specificity of IFN-␥-producing cells generated by DNA-plasmid vaccination was also analyzed in more detail ( Table 2 ). The Th peptide and the CTL peptides (H-2D b ) P4 and, to a lesser extent, P3 triggered IFN-␥ secretion from cells primed with pXJ38. These results are in agreement with those of Zhu et al. (39) , except for peptide P4, which was not studied. Zhu and colleagues also showed that the peptide (aa 65 to 83) that contains our Th peptide (aa 70 to 84) was recognized not only after DNA immunization with pXJ38, but also after natural infection with M. tuberculosis (39) . This observation indicates that our peptide (aa 70 to 84) is a good protective epitope to include in a future DNA vaccine. The unexpected observation that P4 stimulated IFN-␥ secretion from cells primed with pThP3 and vThϩpP3 plasmids can be explained by cross-reactivity, probably due to similarities between the P4 and Th 
a Specific IFN-␥ secretion was measured as IFN-␥ of spleen cells of mice immunized with immunogen ϪIFN-␥ secretion of spleen cells of mice immunized with control vector. Five million spleen cells from DNA-immunized mice were incubated with the indicated antigens for 72 h. Ϫ, Ͻ50 pg/ml ϩ/Ϫ, 50 to 100 pg/ml; ϩ, 100 to 250 pg/ml; ϩϩ, 250 to 500 pg/ml; ϩϩϩ, 500 to 1,000 pg/ml; ϩϩϩϩ, 1,000 to 1,500 pg/ml. and P3 peptides (i.e., YP, AI, and AL sequences [see sequences in Materials and Methods]). These sequences are close to or include the binding sites of the peptide to major histocompatibility complex (MHC) class I molecules, which results in CTL induction. Thus, when P4 is processed and presented to MHC molecules, the P4 might be presented in a very similar configuration to the peptides Th and P3, which will permit recognition by Th-and or P3-specific T cells. These T cells are probably CTLs producing IFN-␥. However, the processing and presentation of P4 can also occur via MHC class II, due to those similarities, with subsequent activation of CD4 ϩ , which can produce the IFN-␥. In conclusion, P4 seems to behave like a promiscuous epitope, being recognized in the context of multiple MHC alleles.
The multiple-epitope DNA plasmids gave stronger and broader Th1 responses than the single-epitope DNA vaccines and were comparable to the ones induced by the plasmid encoding the entire protein ( Table 2 ). Slight differences were also observed between pThP3 and vThϩpP3, the latter being more efficient in inducing cells that secrete more IFN-␥ and recognize additional peptide epitopes. The superior ability of multiple-epitope plasmids to induce IFN-␥-secreting cells might be related to their higher nonmethylated CpG content, which is known to induce IFN-␥ and IL-12 (17, 27) . These cytokines are required for the efficient induction of a Th1 type of immune response. Improvement of the cellular immune response and protection by the coadministration of different plasmids have also been achieved by other researchers. Lee et al. (19) , for example, observed an increase in antigen-specific CTL induction, T-cell proliferation, and specific antibody secretion after coadministration of a plasmid encoding the hemagglutinin of influenza A virus with the empty vector DNA.
Investigation of the antigen-specific humoral response after immunization with different plasmid DNAs did not indicate any increase in the anti-38-kDa antibodies in the sera of mice vaccinated with plasmid vTh, pThP3, or vThϩpP3 (compared with control vector). Such antibodies were only detected in the sera of mice vaccinated with the plasmid encoding the entire 38-kDa protein, pXJ38. These results are in agreement with those obtained by other researchers with DNA vaccines encoding entire protein antigens from M. tuberculosis (39) .
In conclusion, we were able to induce strong antigen-specific CD8 ϩ CTL, Th1 responses, and IgG2a antibody after immunization with pXJ38, which confirmed previous results by Zhu et al. (39) . We also found that the coadministration of vTh and pP3 resulted in the induction of antigen-specific CD8 ϩ CTL and Th1 responses. Both can play a key role in protection against M. tuberculosis. Moreover, the absence of an antigenspecific antibody response after immunization with the epitope-based DNA vaccines provides important advantages compared with whole-protein-based DNA vaccines for tuberculosis. Thus, the development of epitope-based DNA vaccines should be considered when designing prophylactic and therapeutic vaccines to use against M. tuberculosis infection in humans.
